14th Annual CMHC - CME Symposia


 ‌

CME Breakfast Symposium A · Friday, October 11, 2019 · 6:30 – 7:45 AM

Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras

Chaired by: George L. Bakris, MD

Learning Objectives
After completing this activity, the participant should be better able to:

  • Review the association and the pathophysiology between T2D and CKD, and the impact of concomitant CKD and T2D on patient outcomes
  • Employ the diagnostic criteria according to evidence-based guidelines for DKD in patients with T2DM at risk for kidney disease progression
  • Utilize current treatment options for patients with DKD based on identified benefits and risks, and current guideline recommendations
  • Review the efficacy and safety of emerging DKD treatments based on the latest evidence

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.


 ‌

CME Breakfast Symposium A · Saturday, October 12, 2019 · 6:30 – 7:45 AM

The Potassium Dilemma in HF and CKD: Challenges and Advancements in the Management of Hyperkalemia

Chaired by: George L. Bakris, MD

Learning Objectives
After completing this activity, the participant should be better able to:

  • Identify patients at risk for hyperkalemia based on the presence of several modifiable risk factors
  • Evaluate the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies based on evidence-based guideline recommendations for HF management and appropriate monitoring for renal function and hyperkalemia.
  • Interpret the efficacy and safety of current and new treatment options for hyperkalemia
  • Develop appropriate treatment regimens for hyperkalemia in patients with HF and CKD based on the efficacy, safety, and mechanisms of action of current and new therapies.

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from AstraZeneca and Relypsa, Inc.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.


 ‌

CME Lunch Symposium A · Saturday, October 12, 2019 · 12:00 – 1:15 PM

Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection Fraction

Chaired by: Mariell Jessup, MD, FAHA

Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and quality of life.

To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to diagnose and manage HFpEF, including patients with comorbidities. This live symposium will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Identify HFpEF based on current and emerging diagnostic approaches
  • Develop individualized treatment regimens for HFpEF patients with comorbidities based on current guidelines and evidence
  • Interpret the efficacy and safety of emerging treatment options and therapeutic strategies in HFpEF based on the latest clinical trial evidence
  • List approaches and resources aimed to improve hospital readmission rates for patients with HFpEF

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Abbott and Novartis Pharmaceuticals Corporation.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.


 ‌

CME Dinner Symposium · Saturday, October 12, 2019 · 7:20 – 8:35 PM

Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

Chaired by: Christie M. Ballantyne, MD

Learning Objectives
After completing this activity, the participant should be better able to:

  • Identify patients with elevated LDL-C who are statin intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and diagnostic guidelines.
  • List new and emerging treatment options for ASCVD prevention or management in high-risk patients with hypercholesterolemia.
  • Develop individualized treatment regimens for prevention of adverse cardiovascular events in high-risk patients with elevated LDL-C and comorbidities based on the current ACC/AHA guidelines and evidence about the safety and efficacy of non-statin therapies.
  • Employ strategies and resources designed to improve patients’ access to new treatment options for hypercholesterolemia that may minimize risk of adverse cardiovascular events.

This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Multi-supported by educational grants from Sanofi and Esperion.

This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ANCC credit, see final activity announcement for specific details. For overall accreditation information on the 14th Annual CMHC, please click here.